Luminal-A breast cancers (BC) are identified by the expression of hormone receptors (estrogen receptors (ER) and progesterone receptors (PR)) and by the absence of HER2 expression; although this disease subtype is considered as having a relatively favorable outcome, a considerable number of patients experience local recurrence and metastasis [1,2,3]. This evidence concerns the gene ESR1 and breast cancer.